Latest Max Healthcare Stories
New market research report “Private Hospital Services Market In India” elaborated by Kuick Research has been recently published by Market Publishers Ltd.
DUBAI, UAE, August 4, 2011 /PRNewswire/ -- Hospitals across India could be on the brink of finding a solution to closing the gap between the quality of healthcare between city dwellers and those residing in India's villages. Telemedicine, an umbrella term for new technology and techniques that facilitates healthcare diagnosis and treatment remotely, is being hailed by the industry as an answer to ensuring that India's poorer classes have access to the best healthcare...
RESEARCH TRIANGLE PARK, N.C., June 17, 2011 /PRNewswire/ -- Max Neeman International, leading Indian CRO, is part of the prestigious Max Group whose sister-company, Max Healthcare recently had one of 12 hospitals, 'Max Institute of Minimal Access, Metabolic & Bariatric Surgery' accredited as a Center of Excellence (COE) by the Surgical Review Corporation (SRC), USA.
Baylor College of Medicine today announced the first major project of its new Center for Globalization, a plan to partner with a leading health care provider in India in an academic affiliation.
RESEARCH TRIANGLE PARK, N.C., March 1, 2011 /PRNewswire/ -- Max Neeman International has established a team of experts specialized in carrying out rare disease trials in response to sponsor demand.
RESEARCH TRIANGLE PARK, N.C., Feb. 14, 2011 /PRNewswire/ -- India's premier CRO, Max Neeman, participated in the 59th annual Neurological Society of India & Congress of Neurological Surgeons (NEUROCON) held in Jaipur, India this past December.
RESEARCH TRIANGLE PARK, N.C., Jan. 26, 2011 /PRNewswire/ -- Max Neeman International, India's premier CRO, has quadrupled the amount of clinical trials awarded since 2007 and reached the milestone of over 200 in 2010. Per CEO, Dr.
RESEARCH TRIANGLE PARK, N.C., May 25 /PRNewswire/ -- Max Neeman International, a full service Contract Research Organization announces set-up of company central lab services beginning with a Phase II study in Oncology.